Compare MCFT & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | XOMA |
|---|---|---|
| Founded | 1968 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.1M | 471.6M |
| IPO Year | 2015 | N/A |
| Metric | MCFT | XOMA |
|---|---|---|
| Price | $23.53 | $41.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $24.25 | ★ $52.50 |
| AVG Volume (30 Days) | ★ 194.4K | 160.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $284,203,000.00 | N/A |
| Revenue This Year | $9.18 | $24.59 |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $72.39 | ★ $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.46 | $22.29 |
| 52 Week High | $28.44 | $42.81 |
| Indicator | MCFT | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 63.93 |
| Support Level | $19.79 | $37.00 |
| Resistance Level | $23.65 | $42.15 |
| Average True Range (ATR) | 1.07 | 0.32 |
| MACD | -0.15 | -0.32 |
| Stochastic Oscillator | 31.04 | 31.18 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.